NACI issues new guidelines on using AstraZeneca shot for people under 55

Some provinces are suspending the use of Oxford-AstraZeneca’s COVID-19 vaccine for people under 55, following new recommendations by the National Advisory Committee on Immunization (NACI) over concerns about blood clots. Mike Armstrong reports on the roller-coaster advice, and how this could affect Canada’s vaccine rollout.

• Update on AstraZeneca blood clot review coming this week, EU drug regulator says
• With 300,000 AstraZeneca doses set to expire April 2, will provinces use them up?
• Canadians’ trust in Pfizer, Moderna vaccines far outweigh AstraZeneca, poll suggests